Shigeo Katsumata

Title: Shigeo Katsumata: Innovator in Antitumor Compounds

Introduction

Shigeo Katsumata is a notable inventor based in Mishima, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antitumor activity. With a total of 6 patents to his name, Katsumata's work has had a meaningful impact on cancer treatment.

Latest Patents

One of his latest patents is for a compound known as UCE6, which is represented by a specific formula. This compound has demonstrated excellent antitumor activity, making it a promising candidate for further research and development. Another significant patent involves a process for producing staurosporine derivatives. This process reveals a method for creating a staurosporine derivative that possesses selective protein kinase C-inhibitory and cell growth-inhibiting activities, along with platelet-increasing activity.

Career Highlights

Throughout his career, Shigeo Katsumata has worked with prominent companies in the pharmaceutical industry, including Kyowa Hakko Kogyo Co., Ltd. and Kyowa Hakko Kogyo Kabushiki. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in drug development.

Collaborations

Katsumata has collaborated with esteemed colleagues such as Makoto Morimoto and Shinzo Ishii. These partnerships have fostered an environment of innovation and have led to the advancement of various pharmaceutical projects.

Conclusion

Shigeo Katsumata's contributions to the field of pharmaceuticals, particularly in antitumor compounds, highlight his role as a significant inventor. His patents and collaborations reflect a commitment to advancing medical science and improving treatment options for cancer patients.